Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Korenblik R.,Olij B.,Aldrighetti L. A.,Hilal M. Abu, Ahle M.,Arslan B., van Baardewijk L. J., Baclija I.,Bent C.,Bertrand C. L.,Björnsson B.,de Boer M. T., de Boer S. W.,Bokkers R. P. H.,Rinkes I. H. M. Borel,Breitenstein S.,Bruijnen R. C. G.,Bruners P.,Büchler M. W.,Camacho J. C., Cappelli A.,Carling U.,Chan B. K. Y., Chang D. H., choi J., Font J. Codina, Crawford M.,Croagh D.,Cugat E., Davis R., De Boo D. W.,De Cobelli F., De Wispelaere J. F.,van Delden O. M.,Delle M.,Detry O.,Díaz-Nieto R., Dili A.,Erdmann J. I., Fisher O.,Fondevila C.,Fretland Å.,Borobia F. Garcia, Gelabert A., Gérard L.,Giuliante F.,Gobardhan P. D.,Gómez F., Grünberger T.,Grünhagen D. J., Guitart J.,Hagendoorn J.,Heil J.,Heise D., Herrero E.,Hess G. F., Hoffmann M. H.,Iezzi R., Imani F., Nguyen J.,Jovine E.,Kalff J. C.,Kazemier G.,Kingham T. P.,Kleeff J., Kollmar O.,Leclercq W. K. G.,Ben S. Lopez,Lucidi V., MacDonald A.,Madoff D. C.,Manekeller S.,Martel G.,Mehrabi A.,Mehrzad H.,Meijerink M. R.,Menon K.,Metrakos P., Meyer C.,Moelker A.,Modi S., Montanari N.,Navines J.,Neumann U. P.,Peddu P.,Primrose J. N., Qu X.,Raptis D.,Ratti F.,Ridouani F.,Rogan C.,Ronellenfitsch U., Ryan S., Sallemi C., Moragues J. Sampere,Sandström P.,Sarriá L.,Schnitzbauer A.,Serenari M.,Serrablo A.,Smits M. L. J.,Sparrelid E.,Spüntrup E.,Stavrou G. A.,Sutcliffe R. P., Tancredi I.,Tasse J. C., Udupa V.,Valenti D.,Fundora Y., Vogl T. J., Wang X.,White S. A.,Wohlgemuth W. A., Yu D., Zijlstra I. A. J.,Binkert C. A.,Bemelmans M. H. A.,van der Leij C.,Schadde E.,van Dam R. M.

crossref（2024）

引用 10|浏览45

暂无评分

摘要

The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Not applicable. DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).

查看译文

关键词

Colorectal cancer liver metastases (CRLM),Portal vein embolization (PVE),Hepatic vein embolization (HVE),Combined portal- and hepatic vein embolization (PVE/HVE),Liver hypertrophy,Future liver remnant (FLR)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要